Cannell & Co. Axsome Therapeutics, Inc. Transaction History
Cannell & Co.
- $3.01 Billion
- Q4 2023
A detailed history of Cannell & Co. transactions in Axsome Therapeutics, Inc. stock. As of the latest transaction made, Cannell & Co. holds 82,845 shares of AXSM stock, worth $7.72 Million. This represents 0.22% of its overall portfolio holdings.
Number of Shares
82,845
Previous 104,190
20.49%
Holding current value
$7.72 Million
Previous $7.28 Million
9.45%
% of portfolio
0.22%
Previous 0.26%
Shares
6 transactions
Others Institutions Holding AXSM
# of Institutions
326Shares Held
37.7MCall Options Held
912KPut Options Held
855K-
Rtw Investments, LP New York, NY4.19MShares$390 Million6.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4MShares$372 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.3MShares$307 Million0.01% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA2.36MShares$220 Million34.46% of portfolio
-
Bvf Inc San Francisco, CA1.05MShares$97.5 Million2.99% of portfolio
About Axsome Therapeutics, Inc.
- Ticker AXSM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 42,878,000
- Market Cap $3.99B
- Description
- Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinic...